Diabetes in Neuropsychiatric Disorders
- Registration Number
- NCT00446992
- Brief Summary
The purpose of this study was to describe metabolic changes in the first 16 weeks of anti-psychotic treatment in previously drug-naïve patients with psychosis.
We hypothesize that in drug-naive patients, greater insulin resistance prior to treatment predicts a disproportionately greater increase in insulin resistance with olanzapine treatment.
- Detailed Description
Antipsychotic medications are associated with an increased risk of diabetes. We focused on a description of early metabolic adverse effects and clinical and biochemical features that might predict these adverse effects.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Open Trial Group Olanzapine The patients were newly diagnosed with psychosis and were recruited at their first clinical contact for psychosis.
- Primary Outcome Measures
Name Time Method Fasting Insulin Baseline and 4 week intervals Hemoglobin A1c Baseline and 4 week intervals HDL Baseline and 4 week intervals LDL Baseline and 4 week intervals Cholesterol Total Baseline and 4 week intervals Fasting Glucose Baseline and 4 week intervals Triglycerides Baseline and 4 week intervals Body Mass Index Baseline and 4 week intervals IL-6 Baseline and 4 week intervals
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Unitat Hospitalitzacio - Servei de Psiquiatria G096, Hospital Clinic C/Villarroel, 170
🇪🇸Barcelona, Spain